Literature DB >> 27052632

Adenosine-mediated immunosuppression in patients with squamous cell carcinoma of the head and neck.

M Mandapathil1,2.   

Abstract

This review article describes the potential role of ectonucleotidase activity, adenosine metabolism, and the adenosinergic signaling pathway in the suppression of the host immune system in patients with head and neck cancer. Identifying such mechanisms leads to a better understanding of immunosuppressive mechanisms in this patient population. Further, potential targets for immunotherapy in an adjuvant approach to treating squamous cell carcinoma of the head and neck in the future might be identified and improve the prognosis of these patients.

Entities:  

Keywords:  Adenosine; Head and neck cancer; Immunotherapy; Regulatory T cells; Signaling pathways

Mesh：

Substances：

Year:  2016        PMID： 27052632     DOI： 10.1007/s00106-016-0137-7

Source DB:  PubMed          Journal:  HNO        ISSN： 0017-6192            Impact factor:   1.284


  48 in total

1.  Ecto-5'-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells.

Authors:  Li Wang; Xuerui Zhou; Tingting Zhou; Dong Ma; Sifeng Chen; Xiuling Zhi; Lianhua Yin; Zhimin Shao; Zhouluo Ou; Ping Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2007-08-02       Impact factor: 4.553

2.  Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.

Authors:  Sebastian F M Häusler; Itsaso Montalbán del Barrio; Jenny Strohschein; P Anoop Chandran; Jörg B Engel; Arnd Hönig; Monika Ossadnik; Evi Horn; Birgitt Fischer; Mathias Krockenberger; Stefan Heuer; Ahmed Adel Seida; Markus Junker; Hermann Kneitz; Doris Kloor; Karl-Norbert Klotz; Johannes Dietl; Jörg Wischhusen
Journal:  Cancer Immunol Immunother       Date:  2011-06-03       Impact factor: 6.968

3.  Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening.

Authors:  Richard J Rickles; Winnie F Tam; Thomas P Giordano; Laura T Pierce; Melissa Farwell; Douglas W McMillin; Antoaneta Necheva; David Crowe; Mei Chen; William Avery; Vikram Kansra; Steffan T Nawrocki; Jennifer S Carew; Francis J Giles; Constantine S Mitsiades; Alexis A Borisy; Kenneth C Anderson; Margaret S Lee
Journal:  Mol Cancer Ther       Date:  2012-04-03       Impact factor: 6.261

4.  Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents.

Authors:  I Jolanda M de Vries; Chiara Castelli; Caroline Huygens; Joannes F M Jacobs; Julie Stockis; Beatrice Schuler-Thurner; Gosse J Adema; Cornelis J A Punt; Licia Rivoltini; Gerold Schuler; Pierre G Coulie; Sophie Lucas
Journal:  Clin Cancer Res       Date:  2010-12-21       Impact factor: 12.531

Review 5.  Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?

Authors:  Joannes F M Jacobs; Stefan Nierkens; Carl G Figdor; I Jolanda M de Vries; Gosse J Adema
Journal:  Lancet Oncol       Date:  2012-01       Impact factor: 41.316

Review 6.  In situ modulation of oxidative stress: a novel and efficient strategy to kill cancer cells.

Authors:  J Verrax; R Curi Pedrosa; R Beck; N Dejeans; H Taper; P Buc Calderon
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

7.  A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments.

Authors:  Akio Ohta; Akiko Ohta; Manasa Madasu; Radhika Kini; Meenakshi Subramanian; Nipun Goel; Michail Sitkovsky
Journal:  J Immunol       Date:  2009-11-01       Impact factor: 5.422

Review 8.  Epidemiology of human papillomavirus-related head and neck cancer.

Authors:  Andrew W Joseph; Gypsyamber D'Souza
Journal:  Otolaryngol Clin North Am       Date:  2012-05-31       Impact factor: 3.346

9.  The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway.

Authors:  Akio Ohta; Radhika Kini; Akiko Ohta; Meenakshi Subramanian; Manasa Madasu; Michail Sitkovsky
Journal:  Front Immunol       Date:  2012-07-05       Impact factor: 7.561

10.  Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase.

Authors:  Patrizia Pellegatti; Lizzia Raffaghello; Giovanna Bianchi; Federica Piccardi; Vito Pistoia; Francesco Di Virgilio
Journal:  PLoS One       Date:  2008-07-09       Impact factor: 3.240
View more
  2 in total

1.  PD1 blockade enhances K+ channel activity, Ca2+ signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer.

Authors:  Hannah S Newton; Vaibhavkumar S Gawali; Ameet A Chimote; Maria A Lehn; Sarah M Palackdharry; Benjamin H Hinrichs; Roman Jandarov; David Hildeman; Edith M Janssen; Trisha M Wise-Draper; Laura Conforti
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

2.  Targeted knockdown of the adenosine A2A receptor by lipid NPs rescues the chemotaxis of head and neck cancer memory T cells.

Authors:  Hannah S Newton; Ameet A Chimote; Michael J Arnold; Trisha M Wise-Draper; Laura Conforti
Journal:  Mol Ther Methods Clin Dev       Date:  2021-03-04       Impact factor: 6.698
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.